Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- ramucirumab
- Trixylitral (diclofenac / lidocaine topical)
Interactions between your drugs
diclofenac topical ramucirumab
Applies to: Trixylitral (diclofenac / lidocaine topical), ramucirumab
MONITOR: Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.
MANAGEMENT: Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
References (3)
- (2001) "Product Information. Acular (ketorolac)." Allergan Inc
- (2005) "Product Information. Xibrom (bromfenac ophthalmic)." ISTA Pharmaceuticals
- (2005) "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.